drugset / Trial / NCT01614899
A Phase III Study of SM-13496 (Lurasidone HCl) in Patients With Schizophrenia
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The study evaluates the efficacy and safety of SM-13496 compared with placebo in patients with schizophrenia.
Timeline
- Start
- 2012-07-02
- Primary completion
- 2014-11-17
- Completion
- 2014-11-17
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lurasidone | Small molecule | 40 mg | Oral |
| Subject | Lurasidone | Small molecule | 80 mg | Oral |